CrSp Crispr Therapeutics - the next Trillion Dollar Company

6 ม.ค.

Dear reader, I've been following Crispr therapeutics for a long time. It is a fantastic company. They have FDA approval in the United States and in Europe for sickle cell disease that is a melody that are fixed 70 million people and has a market value of $2
.49 trillion.in therapies. Yes that's correct each therapy costs about 2,600,000 and they are 70 million afflicted so even with the 3% of the population being able to pay for this therapy, you get to $2.49 trillion then they have another FDA approved therapy for air condition where the T cells will attack healthy cells. This happens in patients that are recovering from cancer and the population afflicted by this is 3.9% of all cancer patients, which is an enormous amount because cancer is what kills people in old age so that therapy costs about $1 million and has a massive market. Like this therapy Crispr therapeutics, has many other therapies. This is a new technology their friends it is a kin to the discovery of penicillin before penicillin. This is miles ahead of anything, and this therapies will serve to do a number of things to correct food shortages for example plants modify genetically many many many organisms this is just the beginning for now Crispr therapeutics is doing manipulation outside the body sickle cell for example, are extracted manipulated outside and rejected in the patient same with the T cells, but in the future as technology progresses, there will be vaccines that will be in vivo inside of this. I'm sure but even if nothing happens and we continue doing the same things we're doing manipulating cells outside the body Crispr therapeutics is the next trillion dollar company I see this happening within one to two years. The progress is outstanding amazing you should all be looking into it. It's really something else so this is my tip for the year so you can get rich by invest investing in the company that is just now starting to grow.

6 ม.ค.

บันทึก

Here are all the goodies
CRISPR Therapeutics has seen several positive developments recently:
Casgevy Approval and Launch
The company's first CRISPR-based therapy, Casgevy, received regulatory approvals in multiple countries for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in patients 12 years and older. The launch is gaining momentum, with over 35 authorized treatment centers activated globally and approximately 20 patients with cells collected.
Clinical Trial Progress
CTX112
CTX112, a next-generation CD19 allogeneic CAR T cell therapy, has shown promising results in treating relapsed or refractory B-cell malignancies:
67% objective response rate across all dose levels
50% complete response rate
Well-tolerated safety profile
Five patients achieved responses lasting over 6 months
The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX112 for treating R/R follicular lymphoma and marginal zone lymphoma.
In Vivo Gene Editing Programs
CTX310 and CTX320, targeting ANGPTL3 and LPA respectively, are currently in ongoing Phase 1 clinical trials. These programs utilize CRISPR Therapeutics' proprietary lipid nanoparticle platform for liver-targeted gene editing.
Pipeline Expansion
The company has introduced two new preclinical programs:
CTX340: Targeting refractory hypertension
CTX450: Targeting acute hepatic porphyria.
Clinical trials for these programs are set to begin in the second half of 2025.
Financial Strength
As of September 30, 2024, CRISPR Therapeutics reported a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities. This financial stability is expected to support ongoing development for at least 3.6 years without needing to raise additional capital.
With these developments, CRISPR Therapeutics is well-positioned for potential growth in 2025, as the company continues to advance its pipeline and commercialize its first approved therapy.

Boys these therapies are trillion dollar therapies, as there is no cure until now. Crispr Therapeutics is a massive technological breakthrough - and CrSp is 1st to market with 1st to market advantage ... and a factory for these genetic products, that is what they are, genetic therapy products ...

14 ก.พ.

บันทึก

Did you know that just with the two therapies that have been approved, sickle cell disease and the other one related to cancer and T cells being overactive crisper therapeutics has an intrinsic value of $1075 per share. Just do the calculation. 70,000,000 afflicted with sickle cell disease, 5 million new afflicted people per year, and the T cell hyperactive condition on cancer patients flick 7% of all cancer patients. And you know that cancer will be the ultimate killer when you get old. That means that sickle cell therapy is pricing a 2,000,600 per treatment and the sickle cell hyperactive and cancer patients costs $1 million per treatment. I'll leave you with that thought. And by the way, if you think that Pharma will not go for this, you're wrong the payment upfront is much bigger than the payment overtime. And a chronic treatment for a patient afflicted with any of this diseases after you do the NPV net pressing value you realize that Chris therapy it's much better. Not only this, but the government has an incentive to actually cover part of the insurance cost of this therapies so they can integrate patients afflicted into the productive, workforce and generate income from tax revenue. This is why I believe that Chris therapeutics will be licensing very successfully. This therapies to Pharma far and wide, so the only bottleneck was insurance so the government will pick up the insurance that's for sure because it makes sense from a mathematical perspective.